|
Name
|
Recombinant
Murine IL-36β, 153a.a. (Recombinant Murine Interleukin-36β, 153a.a.; rMuIL-36β, 153a.a.)；Recombinant Mouse IL-36β, 153a.a. ; 重組小鼠白細(xì)胞介素36β，153a.a.
|
|
Synonyms
|
FIL1 eta; IL-1
eta; IL1F8; IL-1H2; IL36B; family of interleukin 1-eta; FIL1; FIL1 eta;
FIL1-(ETA); FIL1H; FILI-(ETA); IL-1 eta; IL1-ETA; IL1F8; IL-1F8; IL1F8
(Canonical product IL-1F8a); IL-1F8 (FIL1-eta); IL1H2; IL-1H2; interleukin 1
family, member 8 (eta); interleukin 1, eta; Interleukin 36, Beta;
Interleukin-1 eta; interleukin-1 family member 8; Interleukin-1 homolog 2;
Interleukin-1 Superfamily e; Interleukin-36 Beta
|
|
Background
|
Interleukin-36
is a pro-inflammatory cytokine which plays an important role in the
pathophysiology of several diseases. IL-36α, IL-36β, and IL-36γ (formerly IL-1F6, IL-1F8, and
IL-1F9) are IL-1 family members that signal through the IL-1 receptor family
members IL-1Rrp2 (IL-1RL2) and IL-1RAcP. IL-36 beta is reported to be
expressed at higher levels in psoriatic plaques than in symptomless psoriatic
skin or healthy control skin and it can stimulate production of interleukin-6
and interleukin-8 in synovial fibrobasts, articular chondrocytes and mature
adipocytes. IL-36 beta has two isoforms. IL-36β2
contains one potential N-linked glycosylation site in its C-terminus, while
IL -36β isoform 1 lacks potential N-linked
glycosylation sites and four of the conserved β-strands.
Within the IL-1 family, IL-36β/IL-1F8 shares 30%,
32%, 37%, 46%, 34%, 45% and 28% aa sequence identity with IL-1 ra, IL-1β, IL-36Ra/IL-1F5, IL-36α/IL-1F6,
IL-37/IL-1F7, IL-36γ/IL-1F9 and IL-1F10,
respectively.
|